Press coverage about Zogenix (NASDAQ:ZGNX) has been trending positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.3276633582228 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
ZGNX has been the subject of several recent analyst reports. Mizuho reissued a “buy” rating and set a $51.00 target price on shares of Zogenix in a research note on Wednesday, November 8th. BidaskClub raised shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Stifel Nicolaus restated a “buy” rating and issued a $55.00 price objective (up from $26.00) on shares of Zogenix in a report on Friday, September 29th. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Finally, JMP Securities started coverage on Zogenix in a report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $42.67.
Zogenix (NASDAQ:ZGNX) opened at $35.95 on Friday. The company has a market cap of $1,209.11, a PE ratio of -8.13 and a beta of 1.96. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix has a fifty-two week low of $7.70 and a fifty-two week high of $43.35.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.16). Zogenix had a negative net margin of 309.76% and a negative return on equity of 99.61%. equities analysts predict that Zogenix will post -4.45 EPS for the current fiscal year.
In related news, EVP Bradley S. Galer acquired 1,346 shares of the stock in a transaction on Wednesday, December 13th. The shares were acquired at an average price of $36.59 per share, for a total transaction of $49,250.14. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Roger Hawley sold 11,797 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $37.02, for a total value of $436,724.94. Following the completion of the sale, the director now owns 105,575 shares in the company, valued at approximately $3,908,386.50. The disclosure for this sale can be found here. 5.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Zogenix (ZGNX) Earning Positive Media Coverage, Accern Reports” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/01/21/zogenix-zgnx-earning-positive-media-coverage-accern-reports.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.